Scrip's Five Must-Know Things - Aug. 31, 2026

Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs.

Story links: insights.citeline.com/scrip/podcasts/scrips-fi…

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts (podcasts.apple.com/us/podcast/scrip-podcasts/i…), and Spotify Podcasts (open.spotify.com/show/54Ki1l5bTzuxvrUylwbvO9?s…)and on TuneIn (tunein.com/podcasts/Business--Economics-Podcas…).

Contact us on podcasts@norstella.com.